The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities

Nuclear Medicine Communications

Volumn 32, Issue 2, 2011, Pages 85-90

  Filippi, Vasiliki ^a   Malamitsi, Joulia ^b   Vlachou, Fani ^a   Laspas, Fotios ^a   Georgiou, Evangelos ^b   Prassopoulos, Vasileios ^a   Andreou, John ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

breast cancer; positron emission tomography computed tomography; tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PREDICTIVE VALUE; RADIOGRAPHY;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 78650935810     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328341c898     Document Type: Article

References (18)

1. Van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801trial. J Natl Cancer Inst 2000; 19:1143-1150.
2. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. editors. SEER Cancer Statistics Review, 1975-2001. Bethesda: National Cancer Institute; 2004.
3. Grunfeld E, Mant D, Yudkin P, Dalton RA, Cole D, Stewart J, et al. Routine follow-up for breast cancer in primary care: trial. BMJ 1996; 13:665-669.
4. Lonneux M, Borbath II, Berliere M, Kirkove C, Pauwels S. The place of whole-body PET FDG for the diagnosis of recurrence of breast cancer. Clin Positron Imaging 2000; 3:45-49.
5. Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol 2005; 23:1601-1602. (Pubitemid 46211408)
6. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breastconserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001; 19:1688-1697.
7. Ravaioli A, Pasini G, Polselli A, Papi M, Tassinari D, Arcangeli V, et al. Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat 2002; 72:53-60.
8. Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 2002; 38:1189-1193.
9. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1865-1878.
10. Eubank WB, Mankoff DA, Schmied UP,Winter TC III, Fisher ER, Olshen AB, et al. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. Am J Roentgenol 1998; 171:1103-1110.
11. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005; 90:105-112.
12. Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Schubert EK, Dunnwald LK, et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 2002; 22:5-17.
13. Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, et al. Impact of whole body 18F-FDG PET on staging and managing patients with breast cancer: The referring physicians perspective. J Nucl Med 2001; 42:1334-1337.
14. Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W. The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 2003; 23:1859-1867. (Pubitemid 36750859)
15. SiggelkowW, RathW, Buell U, Zimny M. FDG PET and tumor markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imaging 2004; 31:118-124.
16. Israel O, Mor M, Guralnik L, Hermoni N, Gaitini D, Bar-Shalom R. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? J Nucl Med 2004; 45:2045-2051.
17. Lin EC, Alavi A. PET and PET/CT: a clinical guide. New York, NY: Theime; 2005.
18. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDGPET/ CT in suspected recurrence of breast cancer. Cancer 2006; 107:2545-2551.